Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
11 juil. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety studiesIf approved, roflumilast cream would be...